Nucala 100 mg, Lyophilisat zur Herstellung einer Injektionslösung - Swissmedic Key 65731001 Registration Holder GlaxoSmithKline AG Name Nucala 100 mg, Lyophilisat zur Herstellung einer Injektionslösung Date of registration 07.04.2016 Introduction of Sequence 07.04.2016 ATC-Classification Mepolizumab (R03DX09) Revision date WHO WHO-DDD Valid until Index Therapeuticus (BSV) 03.04.50. Show package size Index Therapeuticus (Swissmedic) 03.04.50. Description Swissmedic categorie. B SL Eintrag Yes Indication Information for professionals IP Consumer information Ex-factory-Price 976.63 Limitation Yes Limitation text
Deductible 10 % Consumer price 1078.55 Feedback FB GTIN 7680657310016 Medication Code Biotechnologika Pharmacode 6653281 Disponibility ●
Composition Praeparatio cryodesiccata: mepolizumabum 100 mg, saccharum, dinatrii phosphas heptahydricus corresp. natrium 1.5-2 mg, polysorbatum 80, acidum hydrochloricum q.s. ad pH pro vitro. Packungsbestandteile Label Praeparatio cryodesiccata:
Galenic Form Lyophilisate Excipiens Active Agent Dose Mepolizumabum 100 mg
BAG: Active Agent Dose Mepolizumabum 100 mg
Inactive agents Hydrochloric Acid Disodium Phosphate Heptahydrate Polysorbatum 80 Saccharum
Source Data was imported : 05.01.2021
Swissmedic Registration :
Sequence :
Product name :
Registration owner: :
Product group :
Index Therapeuticus (BSV) :
Medication Code :
Date of registration :
Valid until :
Package number :
Show package size :
Commercial Form/Unit :
Swissmedic categorie. :
Active Agents :
Composition :
